Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Tred will be back . He is on a two or three month break of some kind.
He always had some great posts and that AI prediction thingy.
Whatever happened to Biostockclub?
Thanks 12x that’s great news! Longs overdue
Partnership with 5bil upfront payment for AD
or EU/ Aus approval for anything!
On ST-MayoMobile 11:38 AM
SAVXL interview with Dr. Grimmer
concluded!
He is warning the rest of us to sell our shares!
Preaching the evils of Avavex night and day!
AND premarket at 8:30am est!
Usually after hours at 4:30
CC on Tuesday is 8:30am vs the normal 4:30.
Does this signal news??
The hiring of Kun Jin is a VERY big deal IMO!
He co-authored papers and worked beside Billy Dunn.
For Anavex to get CNS drugs approved that is a big deal.
The more the merrier. Anavex should promise Billy Dunn a lucrative job when he retires from the FDA…..LOL
Looks to me like Chris Missling knows how to play the game.
The hiring of Dr Jin Kun was a smart move.
In business, many times it’s not what you know, it’s who you know.
You can say what you want about Missing, but in this regard, he is pretty savy and doing what ever it takes to get the job done.
CDER Hall of Fame for Engagement
Office of the Center Director
lanet Woodcock, M.D.
Theresa Mullin, Ph.D.
Terry Toigo, M.P.A, RPh
Sara Eggers, Ph.D.
Office of Drug Evaluation-1
Ellis Unger, M.D.
Bob Temple, M.D.
Division of Neurology Products
Billy Dunn, M.D.
Eric Bastings, M.D.
Nick Kozauer, M.D.
Kun Jin, Ph.D., M.S.
Unfortunately, everything Anavex puts out is met with skepticism.
If it is a peer review, it will be viewed as more credible.
If that’s what you want be believe investor, then sure, WGT!
Nancy Pelosi buys AVXL stock!
From ST board-
Breaking: Chris Jacobs (R) NY just disclosed
over 40 new stock trades
Including 7 new trades in Bio-Technology
companies
He also happens to sit on Biotechnology
House Subcommittee where he has access
to insights that the public does not
BIOTECHNOLOGY. HORTICULTURE. AND RESEARCH
by E. Plaskett, VI, Chair
tel M. Brown, OH
Schrier. WA
y Panetta, CA
le Pingree, ME
Patrick Maloney, NY
O. Carbajal, CA
wson, Jr., FL
Harder, CA
is Correa, CA
James R. Baird, IN
Austin Scott, GA
Eric A. "Rick" Crawford,
Rodney Davis, IL
Don Bacon, NE
Chris Jacobs. NY
Troy Balderson, OH
Michelle Fischbach, MN
Mayra Flores, TX
Brad Finstad, MN
C
32
17 369
O 1,713
Ill 201K
1,
Nancy Pelosi Stock Tracker £ 9. 1d
The trades in question include:
$15K in SAVXL
$15K in SSAVA
$15K in SCOGT
$15K in $KALV
$15K in SKYRS
$15K in SKURA
$15K in $SQTX
O 16
17 45
O
SAVA down 10pct on positive P2 AD results
Sounds familiar
“ Missing has
changed tactics. If..
"the system" is
going to short everything you put
out, you just don't oblige them.
Especially, if you have a big bird in
the hand already.”
Interesting quote from ST message board
“Thus, we must mention that S1R is a therapeutic target for diseases, including AD [93], PD [94], ALS [95,96], and cancer [97]. In fact, there are ongoing phase 2/3 clinical trials for the treatment of Alzheimer’s disease (NCT03790709, NCT04314934) and phase 2 trials for Parkinson’s disease dementia (NCT04575259). These trials are testing ANAVEX2-73 (also known as Blacarmesine), another compound designed as an S1R agonist (and a muscarinic modulator of M1 receptor and a M2/M3 receptors antagonist) [98]. This drug is involved in the modulation of glutamate release, suppression of neuroinflammation, and restoration of cellular functions essential for maintaining neuronal homeostasis processes such as protein folding, calcium regulation, oxidative stress, ER stress, and autophagy [18,19,47,99]. ANAVEX2-73 has shown not only neuroprotective effects but also anticonvulsant, antiamnesic, and antidepressant properties in various animal models [98,99]. Furthermore, pridopidine (also known as ACR16 or Huntexil®) is currently being investigated in a phase 2 clinical trial for the treatment of ALS (NCT04615923). Initially developed for the treatment of Huntington’s disease (HD) associated motor symptoms (reviewed in [18,100]), pridopidine has been shown to protect cells from apoptosis and to improve motor function in an HD mouse model (R6/2). It was shown to: (i) rescue mitochondrial functions and to preserve MAM integrity in human neural stem cells and an HD mouse model (YAC128) [101], (ii) reduce ER stress by modulating all branches of the UPR response in a mHtt (mutant huntingtin) cell line [102], and (iii) protect neurons from mHTT toxicity to decrease cell death [103]. Pridopidine was also shown to decrease neuron death, to conserve neuro-muscular junctions (NMJ), and to restore and enhance axonal transport in primary myocytes and motoneurons cell culture derived from wild-type and SOD1-G93A mice (ALS mouse model) [96]. As of now, targeting S1R activity in neurodegenerative disorders shows great potential. However, combining S1R agonists with other treatments needs to be considered for further analysis of beneficial outcomes. Finally, given that neurosteroids can bind to S1R and modulate its activity, more studies are required to fully understand the effect of aging and biological sex on S1R activity. These studies could help to better estimate S1R therapeutic potency when evaluating its functions in age- and sex-related neurodegenerative disorders.”
https://www.mdpi.com/1422-0067/24/3/1971
Thanks Rubyred!
OMG! It’s Getting worse by the minute!!
I’m starting to panaic! The sky is falling
Didn’t we just go through this?
I agree with that!
Hopefully soon
If the PR was false information, the PR would be deleted.
Stop with the FUD ffrol. Be an investor.
I just checked the website, an found it easily.
Tuesday would be better as the market is closed tomorrow
I just signed in as a returning visitor and it worked fine.
Maybe try first time user?
I didn’t expect the AD data today,however, I really thought there would be a PR about RETT completion or one of the other overdue catalysts .
Maybe he will update the new timelines today
8:15am pacific time is 11:15 est
https://worldfinancialreview.com/how-digital-innovation-is-changing-life-sciences-and-the-way-we-treat-dementia/
Another bullish article by Jessica Wong
It seems that there are a lot of increasingly frustrated shareholders, including myself.
And to be honest, I’m not counting on getting the data at or before the conference next week.
I realize that right now they are focused on the AD situation, but what about the other 6 overdue catalysts?
I’m still puzzled about what can possibly be taking so long to recruit a handful of additional RETT girls. Yes, I understand the Covid delay.
Let’s see what next week brings.
This is gaining traction! Talk radio host Erick Erickson just did a segment on this on his show today. He talked about the time has come to move in a different direction in AD research!
Perfect timing for Anavex!
4th death from lecanemab?
https://www.medscape.com/viewarticle/986510
How will an uplist happen ? Reverse split? Hope not.
Or the bigger questions, what will be the implications to Anavex if approved?
Positive or negative?
Will it set a new, very low bar?